Latrophilin 3, a Gene Involved in Attention Deficit Hyperactivity Disorder
Description of Invention:
Attention Deficit Hyperactivity Disorder (ADHD) is the most common behavioral disorder in childhood, and is estimated to affect three to five percent of people in the United States, both children and adults. Treatment typically involves a combination of behavior modification, educational interventions, and medication. There are a variety of medications available for treatment of ADHD; the most frequently prescribed drugs are stimulants or antidepressants. However, currently there is no way to tell in advance which medication will be most helpful for a particular individual.
The inventors have identified haplotypes of latrophilin 3 (LPHN3) that increase susceptibility for development of ADHD. LPHN3 is a G-protein coupled receptor that is specifically expressed in the brain’s mesolimbic system, which is associated with ADHD. The invention describes methods of identifying LPHN3 haplotypes in an individual for determining susceptibility for development of ADHD. Identification of LPHN3 haplotypes in an ADHD-affected individual may also make possible individualized drug treatment plans.
Applications:
Identify individuals with enhanced susceptibility for ADHD
Use LPHN3 haplotype information to design individualized treatments
Patent Status:
DHHS Reference No. E-312-2006/0 --
U.S. Provisional Application No. 60/850,972 filed 11 Oct 2006
PCT Application No. PCT/US07/79616 filed 27 Sep 2007, which published as WO 2008/045687 on 17 Apr 2008
Licensing Status: Available for exclusive or nonexclusive licensing.
Portfolios: Internal Medicine Central Nervous System
Central Nervous System -Diagnostics Internal Medicine-Diagnostics
For Additional Information Please Contact: Charlene A. Sydnor Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301/435-4689
Email: sydnorc@mail.nih.gov
Fax: 301/402-0220
